Associated Papers
Synchronous diagnosis of multicentric glioma with distinct isocitrate dehydrogenase molecular profiles: a case report.
Mohan AA et al.
Cns Oncology, 2026
A Case of IDH-Mutant Astrocytoma Harboring an IDH2 R172_H173delinsSN Variant.
Auen T et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology, 2026
Gene duplication is associated with gene diversification and potential neofunctionalization in lung cancer evolution.
Ashford P et al.
Genome Research, 2026
Portable duplex digital PCR for on-site detection of IDH mutations in gliomas.
Jung D et al.
Biosensors & Bioelectronics, 2026
Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.
Fujimoto K et al.
Acta Neuropathologica, 2026
Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.
Dai Q et al.
Chemistry & Biodiversity, 2026
Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.
Jones RL et al.
Nature Communications, 2026
PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype.
Stasik S et al.
Annals of Hematology, 2026
Clinicopathologic and molecular characterization of uterine and ovarian mixed yolk sac tumor and carcinoma/carcinosarcoma: implications for somatic derivation and therapeutics.
Zhao J et al.
Virchows Archiv : an International Journal of Pathology, 2026
Diffuse low-grade glioma with a rare BRAF p.T599dup mutation in a child: importance of clinicopathological and molecular correlation.
Yamada S et al.
Brain Tumor Pathology, 2026
Evaluation of the Idylla IDH1-2 Mutation Assay for the Detection of IDH Variants in Solid Tumors and Hematological Malignancies.
Gilson P et al.
International Journal of Molecular Sciences, 2026
Germline variants in ATM, BRCA2, other cancer predisposition and novel candidate genes are implicated in glioma risk in adult glioma patients with a familial or personal history of tumors.
Brand F et al.
Acta Neuropathologica, 2026
Autopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells.
Hu L et al.
Nature Chemical Biology, 2026
NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.
Chonabayashi K et al.
Leukemia, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Comprehensive Genomic Profiling Across Diverse Solid Tumors: A Real-World Experience From India With FoundationOne®CDx Testing.
Julka PK et al.
Cureus, 2026
Clonal hematopoiesis associates with prevalent and incident cardiometabolic disease in a cardiac catheterization cohort.
Regan JA et al.
Plos One, 2026
Tall cell carcinoma with reversed polarity of the breast harbouring IDH1 hotspot mutation: morphologic, immunohistochemical and genetic characterization of two cases.
Krings G et al.
Histopathology, 2025
Genomic characterization of colorectal tumors: insights into significantly mutated genes, pathways, and survival outcomes.
Harrison TA et al.
Bmc Cancer, 2025
Clonal architecture of FLT3-ITD and acquired 13q uniparental disomy define prognostic heterogeneity and therapeutic vulnerabilities in acute myeloid leukemia.
Lai A et al.
Neoplasia (new York, N.y.), 2025
Integrative machine learning-guided in silico and in vitro approach reveals selective small molecule inhibitors targeting mutant IDH1.
Bajaj M et al.
Rsc Advances, 2025
Ultrasensitive Detection of Rare Mutations via Amplifying-Cleaving-Enriching in Acute Myeloid Leukemia.
Zhuang X et al.
Biomedicines, 2025
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib.
Chien KS et al.
Clinical Lymphoma, Myeloma & Leukemia, 2025
Identification and structure-activity relationship optimization of dibromoacetophenones as novel mIDH1 inhibitors.
Li C et al.
European Journal of Medicinal Chemistry, 2025
Programmable Argonaute-mediated single-nucleotide variant sequencing of cell-free DNA for multi-cancer early detection.
Guo C et al.
Nature Communications, 2025
Ancestry-dependent patterns of somatic mosaicism and clonal hematopoiesis mutations in over 125,000 individuals reveal distinct cancer associations.
Colin-Leitzinger C et al.
Human Genomics, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.
Harding JJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Advances in the management of patients with IDH-mutant glioma.
Rossi J et al.
The Oncologist, 2025
Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
Voss RK et al.
Leukemia, 2025
IDH1 mutation in acute lymphoblastic leukemia-A rare but significant finding.
Buzzatti E et al.
Current Research in Translational Medicine, 2025
Clonal hematopoiesis in apparent treatment-resistant hypertension, insights from multiple medical centers and community-based cohorts.
Lv C et al.
Nature Aging, 2025
PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7.
Colón-Ríos DA et al.
Nar Cancer, 2025
DNA polymerase epsilon-mutant colorectal cancers: Insights into non-exonuclease domain mutation variants, microsatellite instability status, and co-mutation profiles.
Taskiran I et al.
World Journal of Gastroenterology, 2025
Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
Cheng WY et al.
Blood, 2025
Enabling whole genome sequencing analysis from FFPE specimens in clinical oncology.
Domenico D et al.
Nature Communications, 2025
Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma.
Cross W et al.
Genome Biology, 2025
A Comprehensive Analysis of Novel Variations Associated with Bile Duct Cancer: Insights into Expression, Methylation, and 3D Protein Structure.
Bülbül A et al.
International Journal of Molecular Sciences, 2025
Double nonallelic somatic activating oncogene variants in a series of mosaic vascular anomalies.
Kuentz P et al.
The British Journal of Dermatology, 2025
IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.
Hoff FW et al.
Haematologica, 2025
Discovery and structure-activity relationship study of novel hydantoin-based inhibitors targeting mutant isocitrate dehydrogenase 1 (mIDH1).
Luo D et al.
European Journal of Medicinal Chemistry, 2025
Unveiling splicing disruptions due to common somatic variants in acute myeloid leukemia.
Morote-Faubel M et al.
Human Genomics, 2025
EGFR transcript variants: Potential diagnostic biomarker for glioblastoma, IDH-wildtype?
Cook DJ et al.
Journal of Neuropathology and Experimental Neurology, 2025
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.
Bazhenova L et al.
Clinical Lung Cancer, 2025
MALNC: a new mutant NPM1/IDH2R140 and PML-RARA-associated lncRNA with impact on AML cell proliferation, maturation and drug response.
Cozzi E et al.
Cancer Gene Therapy, 2025